NCT03333694 - Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

November 1, 2018

Study Completion Date

November 1, 2018

Conditions

Cutaneous Squamous Cell Carcinoma in Situ (CSCCis)

Interventions

DRUG

Cutaneous Cream application

Cutaneous Cream application twice daily with experimental (CLL442)

DRUG

Placebo Cutaneous Cream application

Cutaneous Cream application twice daily with placebo

Trial Locations (8)

Novartis Investigative Site, Westmead

Novartis Investigative Site, Phillip

Novartis Investigative Site, Leuven

Novartis Investigative Site, Liège

Novartis Investigative Site, Benowa

Novartis Investigative Site, Gainesville

Novartis Investigative Site, Phoenix

Novartis Investigative Site, Fountain Valley